AMGN·Healthcare·Biotech
Amgen Earnings -5.3% Plunge: Guidance Shock Despite Upgrade
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…
AMGN·Healthcare·Biotech
Are the latest Amgen Earnings a buying opportunity after the stock’s sudden plunge, or a warning sign that growth is…
NVO·Healthcare·Pharma
Will the Novo Nordisk FDA Compounding crackdown finally shut down GLP‑1 copycats and supercharge the branded obesity drug boom? Maik…
ABBV·Healthcare·Dividend Aristocrats
Are AbbVie Earnings and a surprise Bank of America upgrade signaling a new phase in the pharma giant’s post-Humira transition?…
LLY·Healthcare·Pharma
Are Eli Lilly earnings finally proving that the GLP‑1 obesity boom can justify today’s sky‑high valuation? Maik Kemper Editor in…
LLY·Healthcare·Pharma
Can Eli Lilly’s explosive GLP-1 demand and raised outlook really justify one of the richest valuations in global pharma? Maik…
LLY·Healthcare·Pharma
Is the latest Eli Lilly Acquisition of Ajax Therapeutics a smart oncology pivot or a risky $2.3 billion side bet?…
ISRG·Healthcare·Pharma
Can blockbuster Intuitive Surgical Earnings and a sharp stock surge finally silence the skeptics circling robotic surgery growth? Maik Kemper…
LLY·Healthcare·Pharma
Can the latest Eli Lilly Acquisition in next‑gen cancer therapy really justify its sky‑high valuation beyond the obesity drug boom?…
JNJ·Healthcare·Dividend Aristocrats
Can Johnson & Johnson’s latest earnings surge and dividend hike still justify its premium valuation for long-term investors? Maik Kemper…
NVO·Healthcare·Pharma
Can the Novo Nordisk AI Partnership with OpenAI turn a battered obesity champion into the next big winner of the…